Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study

Area of Science:

• Neurology
• Rehabilitation Medicine
• Pharmacology

Background:

• Reflex sympathetic dystrophy (RSD) negatively impacts rehabilitation in hemiplegic patients, causing pain and functional deficits.
• RSD is a significant complication following cerebrovascular events, hindering recovery.
• Effective management of RSD in hemiplegia is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of salmon calcitonin in treating reflex sympathetic dystrophy in hemiplegic patients.
• To assess the impact of salmon calcitonin on pain, range of motion, and motor function in this patient population.

Main Methods:

• A randomized controlled trial involving 41 hemiplegic patients with stage 1-2 RSD.
• Patients received either salmon calcitonin (100 IU/day IM for 4 weeks) or physiological saline (control group).
• Pain scores, shoulder abduction/external rotation, wrist flexion, and metacarpophalangeal extension were measured.

Main Results:

• The salmon calcitonin group exhibited significantly lower pain scores compared to the control group.
• Significant improvements in shoulder abduction, external rotation, wrist flexion, and metacarpophalangeal extension were observed in the calcitonin group.
• Reduced pain and tenderness correlated with improved range of motion and motor functions.

Conclusions:

• Salmon calcitonin is an effective treatment for reflex sympathetic dystrophy in hemiplegic patients.
• Calcitonin therapy can alleviate pain and enhance motor function, thereby facilitating rehabilitation.
• This treatment offers a promising approach to managing RSD complications in stroke survivors.